President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment. The new rule, which was proposed by the administration Tuesday,